Syros Pharmaceuticals (SYRS) News Today

Syros Pharmaceuticals (NASDAQ:SYRS) will be releasing earnings before the market opens on Wednesday, July 31, Zacks reports.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) - Brookline Capital Management dropped their FY2028 earnings per share estimates for shares of Syros Pharmaceuticals in a research report issued to clients and investors on Tuesday, June 25th. Brookline Capital Management analyst L. Cann now

Opaleye Management Inc. bought a new position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 359,370 shares of the company's stock, val

Flagship Pioneering Inc. raised its holdings in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) by 30.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,293,848 shares of the company'

Bain Capital Life Sciences Investors LLC raised its position in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) by 29.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 2,749,808 shares of the company's stock after acquiring an additional 625,114 shares

Assenagon Asset Management S.A. grew its position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) by 576.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 169,999 s

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) - Investment analysts at Brookline Capital Management boosted their FY2025 EPS estimates for Syros Pharmaceuticals in a research note issued to investors on Tuesday, May 14th. Brookline Capital Management analyst L. Cann now anticipates that

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) - Stock analysts at Brookline Capital Management cut their FY2026 EPS estimates for shares of Syros Pharmaceuticals in a research note issued to investors on Tuesday, May 14th. Brookline Capital Management analyst L. Cann now forecasts that

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.10. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative return on equity of 227.91%. During the same quarter in the prior year, the business earned ($0.85) earnings per share.

HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Syros Pharmaceuticals in a research note on Wednesday.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Get Free Report) was the target of a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 1,450,000 shares, a decline of 22.0% from the April 15th total of 1,860,000 shares. Based on an average daily trading volume, of 196,500 shares, the days-to-cover ratio is presently 7.4 days. Currently, 7.8% of the shares of the stock are sold short.

Syros Pharmaceuticals (NASDAQ:SYRS) Stock Price Crosses Below 50 Day Moving Average of $5.94

StockNews.com downgraded Syros Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday.

Piper Sandler reissued an "overweight" rating and issued a $13.00 price objective on shares of Syros Pharmaceuticals in a research note on Wednesday.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) - HC Wainwright cut their Q1 2024 earnings per share (EPS) estimates for shares of Syros Pharmaceuticals in a report issued on Monday, April 1st. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($1.20) per

HC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of Syros Pharmaceuticals in a report on Monday.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Get Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 1,740,000 shares, a growth of 31.8% from the February 29th total of 1,320,000 shares. Based on an average trading volume of 212,500 shares, the short-interest ratio is currently 8.2 days. Currently, 9.6% of the shares of the company are short sold.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) - Research analysts at Brookline Capital Management raised their Q1 2024 earnings estimates for Syros Pharmaceuticals in a research note issued to investors on Wednesday, March 27th. Brookline Capital Management analyst L. Cann now forecasts

StockNews.com raised shares of Syros Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) - Analysts at Brookline Capital Management issued their FY2028 earnings estimates for Syros Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 27th. Brookline Capital Management analyst L. Cann expects t

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 29th, there was short interest totalling 1,320,000 shares, an increase of 29.4% from the February 14th total of 1,020,000 shares. Currently, 7.3% of the company's stock are short sold. Based on an average daily volume of 320,300 shares, the days-to-cover ratio is presently 4.1 days.